Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | ANPEP | P15144 | 1/20 | 0.56 |
| ▸ | MMP1 | P03956 | 2/20 | 0.55 |
| ▸ | FCER2 | P06734 | 2/20 | 0.55 |
| ▸ | ACE | P12821 | 4/20 | 0.55 |
| ▸ | CPA1 | P15085 | 4/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.55 |
| ▸ | MMP8 | P22894 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3785458 | 1.00 | MME (0.60) | MMEALDH1A1ANPEPMMP1FCER2 | |
| SCHEMBL12341129 | 1.00 | MME (0.60) | MMEALDH1A1ANPEPMMP1FCER2 | |
| SCHEMBL3785450 | 1.00 | MME (0.60) | MMEALDH1A1ANPEPMMP1FCER2 | |
| SCHEMBL17624753 | 0.88 | MME (0.67) | MMEACECPA1ACE2NPSR1 | |
| SCHEMBL12341128 | 0.86 | ATM (0.71) | ALDH1A1MMP8ATM | |
| SCHEMBL3788173 | 0.86 | ATM (0.71) | ALDH1A1MMP8ATM | |
| SCHEMBL3788179 | 0.86 | ATM (0.71) | ALDH1A1MMP8ATM | |
| SCHEMBL12344220 | 0.86 | ATM (0.71) | ALDH1A1MMP8ATM | |
| SCHEMBL3788164 | 0.86 | ATM (0.71) | ALDH1A1MMP8ATM | |
| SCHEMBL714386 | 0.84 | KMT2A (0.59) | MMEALDH1A1MMP8MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2116526-B1 | DERIVATES OF SUBSTITUTED TARTARIC AICD AND USAGE FOR PREPARATING BETA SECRETASE INHIBITORS | INST PHARMACOLOGY & TOXICOLOGY ACADEMY MILITARY MEDICAL SCIENCES PLA CHINA (CN) | 2018-04-18 | — | — | EP | claimed |
| US-8268884-B2 | Derivatives of substituted tartaric acid and usage for preparing beta-secretase inhibitors | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2012-09-18 | — | — | US | claimed |
| US-20100331345-A1 | DERIVATIVES OF SUBSTITUTED TARTARIC ACID AND USAGE FOR PREPARING BETA-SECRETASE INHIBITORS | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2010-12-30 | — | — | US | claimed |
| EP-2116526-A1 | DERIVATES OF SUBSTITUTED TARTARIC AICD AND USAGE FOR PREPARATING BETA SECRETASE INHIBITORS | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) | 2009-11-11 | — | — | EP | claimed |
| EP-2116526-B1 | DERIVATES OF SUBSTITUTED TARTARIC AICD AND USAGE FOR PREPARATING BETA SECRETASE INHIBITORS | INST PHARMACOLOGY & TOXICOLOGY ACADEMY MILITARY MEDICAL SCIENCES PLA CHINA (CN) | 2018-04-18 | — | — | EP | disclosed |
| US-8268884-B2 | Derivatives of substituted tartaric acid and usage for preparing beta-secretase inhibitors | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2012-09-18 | — | — | US | disclosed |
| US-20100331345-A1 | DERIVATIVES OF SUBSTITUTED TARTARIC ACID AND USAGE FOR PREPARING BETA-SECRETASE INHIBITORS | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2010-12-30 | — | — | US | disclosed |
| EP-2116526-A1 | DERIVATES OF SUBSTITUTED TARTARIC AICD AND USAGE FOR PREPARATING BETA SECRETASE INHIBITORS | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) | 2009-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331345-A1 | DERIVATIVES OF SUBSTITUTED TARTARIC ACID AND USAGE FOR PREPARING BETA-SECRETASE INHIBITORS | BACE1, APP, BACE2 | MME 36/4885ALDH1A1 692/4885ANPEP 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.